论文部分内容阅读
In this paper,the safety and efficacy of 131I-labeled mouse/human chimeric monoclonal antibody(131I-chTNT)-mediated radioimmunotherapy are evaluated because the patients have non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma(DTC).The 16 patients were injected intravenously by 29.6±3.7MBq·kg–1 using 131I-chTNT.The chest computer tomography was performed before treatment,as well as 28 and 70days after treatment.Responses and safety were assessed during the treatment.The results show that the 131I-chTNT infusion was well tolerated with the 12.5%complete response,18.8%partial response,25.0%progressive disease,and the 43.8%stable disease,indicating that most treatment-related adverse effects are mild transient and reversible.The131I-chTNT is promising for patients with non-uptaking the 131I pulmonary metastases from DTC.
In this paper, the safety and efficacy of 131I-labeled mouse / human chimeric monoclonal antibody (131I-chTNT) -mediated radioimmunotherapy were evaluated as the patients have non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma (DTC). The 16 patients were injected intravenously by 29.6 ± 3.7 MBq · kg -1 using 131I-chTNT. The chest computer tomography was performed before treatment, as well as 28 and 70 days after treatment. Responses and safety were evaluated during the treatment. The results show that the 131I- chTNT infusion was well tolerated with the 12.5% complete response, 18.8% partial response, 25.0% progressive disease, and the 43.8% stable disease, indicating that the most treatment-related adverse effects were mild transient and reversible. The 131I-chTNT is promising for patients with non-uptaking the 131 I pulmonary metastases from DTC.